US-based Shore Capital Partners has announced the merger of Care Fusion Rx and Reliant Healthcare, creating a national infusion therapy platform serving patients across home and ambulatory care settings.
Care Fusion is Shore Capital Healthcare Advantage Fund’s platform investment.
The combined entity aims to expand access to infusion therapies throughout the US while maintaining a patient-centred approach to care, and will be guided by an experienced management team.
Care Fusion and Reliant will collaborate to enhance the patient experience and engage with referring clinicians and payors to ensure continuity of care services.
Reliant offers ambulatory infusion centre services and home infusion therapy, managing 14 centres and several speciality pharmacies throughout Oklahoma, Louisiana and Texas.
Care Fusion, which was founded in 2020, specialises in complex treatments.
The combined organisation supports several patients across conditions including rare diseases, neurology, oncology, immunology, gastroenterology and rheumatology.
It brings together Reliant’s footprint in home and ambulatory infusion services across the south of the country with Care Fusion’s capabilities in advanced immunoglobulin treatments across the West Coast.
The merged company plans to pursue national growth through the opening of new centres, expanding home infusion territories and undertaking strategic acquisitions in both underserved infusion and high growth markets.
Reliant Healthcare CEO Brad Smith stated: “This partnership represents a tremendous opportunity to enhance how and where patients receive infusion therapy.
“By combining two organisations with deep clinical expertise and shared values, we are creating a platform capable of delivering even more consistent, accessible, affordable and compassionate care to patients who rely on these therapies every day.”
Care Fusion Rx co-founder Steve Roberts stated: “Joining forces with Reliant allows us to extend that commitment to more patients, leverage our combined operational strengths and continue improving outcomes for individuals living with chronic and rare conditions.”
